GenEdit

Main focus: Next-generation delivery systems

Company stage: Pre-clinical

Diseases (gene editing): Undisclosed

Genome editing tool: CRISPR

Funding stage: Private

Location: San Francisco, CA, USA

Website: https://genedit.com/

Gene editing partnerships: Sarepta Therapeutics

GenEdit develops next-generation in vivo gene delivery systems. The company raised $26M in a Series A funding round in September 2021. The technology is based on non-lipid polymer nanoparticles, and the company yet has to disclose its leading pre-clinical programmes.

GenEdit

Your Latest CMN News

CMN Weekly (25 April 2025) - Your Weekly CRISPR...

CMN Weekly

Apr. 25, 2025

Some of the best links we picked up around the internet

Oral TRAP1-Targeting CRISPR Therapy Boosts...

CMN Briefs

Apr. 24, 2025

Researchers in China report that orally-administered CRISPR-Cas9-loaded nanoparticles, designed to target the mitochondrial chaperone TRAP1, overcome...

CRISPRMED25 Poster Prize Winners Highlight Diverse...

Apr. 22, 2025

CRISPR Medicine News spoke with the four CRISPRMED25 poster prize winners to learn more about their research.

CelFi Assay Tracks Indels to Validate CRISPR...

CMN Briefs

Apr. 21, 2025

A new CRISPR-based method has been developed to functionally validate hits from pooled knockout screens by measuring shifts in indel profiles that...

Wrapping up CRISPRMED25, and Gearing up for...

Apr. 18, 2025

CMN Editor-in-chief Karen O’Hanlon Cohrt shares highlights from the second CRISPR Medicine Conference, CRISPRMED25, held last week in Copenhagen.

Light-activated crRNAs enable controlled CRISPR...

CMN Briefs